TOP > 外国特許検索 > CYTOKINE STORM INHIBITOR

CYTOKINE STORM INHIBITOR

外国特許コード F160008833
整理番号 (S2015-0245-N0)
掲載日 2016年8月10日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP085693
国際公開番号 WO 2016104436
国際出願日 平成27年12月21日(2015.12.21)
国際公開日 平成28年6月30日(2016.6.30)
優先権データ
  • 特願2014-258546 (2014.12.22) JP
  • 特願2015-154972 (2015.8.5) JP
発明の名称 (英語) CYTOKINE STORM INHIBITOR
発明の概要(英語) The present invention addresses the problem of providing a novel cytokine storm inhibitor. The present invention is a cytokine storm inhibitor that uses HRG as an active ingredient, based on the discovery that HRG acts to inhibit a plurality of types of cytokines. HRG also acts to inhibit inflammatory cytokines and anti-inflammatory cytokines. The present invention is also a drug for preventing or treating systemic inflammatory response syndrome (SIRS), the drug including this cytokine storm inhibitor having HRG as an active ingredient. According to this cytokine storm inhibitor, it is possible to suppress the elevation, in the blood or lung tissue, of levels of two or more cytokines selected from a plurality of types of cytokines, e.g., IL-6, TNF-α, IL-10, KC (CXCL1), MCP-1 (CCL2), MIG (CXCL9), and MIP-1 alpha (CCL3).
特許請求の範囲(英語) [claim1]
1. It contains the histidine rich glycoprotein, as the active ingredient the sight Cain storm inhibiter.
[claim2]
2. By the sight Cain storm inhibiter, in the blood and/or IL-6, TNF-.alpha., IL-10 and KC which are in the midst of lung organizing (CXCL1), MCP-1 (CCL2), MIG (CXCL9) and MIP-1 alpha (CCL3) from sight Cain of 2 kinds or more which are selected is controlled, in claim 1 the sight Cain storm inhibiter of statement.
[claim3]
3. The histidine rich glycoprotein, refining the histidine which is produced with the human blood component or the technique of gene recombination by the animal cell rich glycoprotein, making use of the affinity gel chromatography roughly, it is the protein which can, in claim 1 or 2 the sight Cain storm inhibiter of statement.
[claim4]
4. The histidine rich glycoprotein, is the histidine rich glycoprotein which is produced by the technique of gene recombination, in claim 3 the sight Cain storm inhibiter of statement.
[claim5]
5. It refines the histidine which is produced as the active ingredient the histidine rich glycoprotein as a production method of the sight Cain storm inhibiter which it contains, by the human blood component or the animal cell rich glycoprotein, making use of the affinity gel chromatography roughly, it features that the process which manufactures the histidine rich glycoprotein as a active ingredient is included, production method of the sight Cain storm inhibiter.
[claim6]
6. Either of the claim 1-4 the sight Cain storm inhibiter of statement is included in 1, systemic characteristic inflammation reaction syndrome (SIRS) the preventive medicine or the remedy medicine.
[claim7]
7. Either of the claim 1-4 it features that the sight Cain storm inhibiter of statement is used for 1, in the blood and/or IL-6, TNF-.alpha., IL-10 and KC which are in the midst of lung organizing (CXCL1), MCP-1 (CCL2), MIG (CXCL9) and MIP-1 alpha (CCL3) from the sight Cain storm control method of controlling sight Cain of 2 kinds or more which are selected.
[claim8]
8. Either of the claim 1-4 it features that the sight Cain storm inhibiter of statement is used for 1, systemic characteristic inflammation reaction syndrome (SIRS) preventive or remedy method.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OKAYAMA UNIVERSITY
  • 発明者(英語)
  • NISHIBORI MASAHIRO
  • MORI SHUJI
  • WAKE HIDENORI
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close